Diagnostic performance of TILs-US score and LPBC in biopsy specimens for predicting pathological complete response in patients with breast cancer.
Breast cancer
LPBC
Neoadjuvant chemotherapy
Pathological complete response
TILs
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
03 Oct 2024
03 Oct 2024
Historique:
received:
14
06
2024
accepted:
20
09
2024
medline:
4
10
2024
pubmed:
4
10
2024
entrez:
3
10
2024
Statut:
aheadofprint
Résumé
Tumor-infiltrating lymphocytes-ultrasonography (TILs-US) score is used to predict lymphocyte-predominant breast cancer (LPBC) in surgical specimens. We aimed to compare diagnostic performance of TILs-US score for predicting pathological complete response (pCR) with that of LPBC in biopsy specimens. TILs ≥ 50% in biopsy specimens was defined as biopsy-LPBC, and TILs-US score ≥ 4 was categorized as TILs-US score-high. Basic nomogram for pCR was developed using stepwise logistic regression based on the smallest Akaike Information Criterion, and biopsy-LPBC and TILs-US score nomograms were developed by integrating biopsy-LPBC or TILs-US scores into a basic nomogram. The diagnostic performance of the nomograms for pCR was compared using area under the curve (AUC), categorical net reclassification improvement (NRI), and integrated discrimination improvement (IDI). This retrospective study evaluated 118 patients with breast cancer, including 33 (28.0%) with biopsy-LPBC, 52 (44.1%) with TILs-US score-high, with 34 (28.8%) achieving pCR. The sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and AUC for predicting pCR were 0.53, 0.82, 2.96, 0.57, and 0.68, respectively, for biopsy-LPBC, and 0.76, 0.69, 2.47, 0.34, and 0.73, respectively, for TILs-US score. The biopsy-LPBC nomogram showed significant improvements in categorical NRI (p = 0.023) and IDI (p = 0.007) but not in AUC (p = 0.25), compared with the basic nomogram. The TILs-US nomogram exhibited significant improvements in AUC (p = 0.039), categorical NRI (p = 0.010), and IDI (p < 0.001). The TILs-US score may serve as a novel marker for prediction of pCR in patients with breast cancer. An external validation study is warranted to confirm our findings.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor-infiltrating lymphocytes-ultrasonography (TILs-US) score is used to predict lymphocyte-predominant breast cancer (LPBC) in surgical specimens. We aimed to compare diagnostic performance of TILs-US score for predicting pathological complete response (pCR) with that of LPBC in biopsy specimens.
METHODS
METHODS
TILs ≥ 50% in biopsy specimens was defined as biopsy-LPBC, and TILs-US score ≥ 4 was categorized as TILs-US score-high. Basic nomogram for pCR was developed using stepwise logistic regression based on the smallest Akaike Information Criterion, and biopsy-LPBC and TILs-US score nomograms were developed by integrating biopsy-LPBC or TILs-US scores into a basic nomogram. The diagnostic performance of the nomograms for pCR was compared using area under the curve (AUC), categorical net reclassification improvement (NRI), and integrated discrimination improvement (IDI).
RESULTS
RESULTS
This retrospective study evaluated 118 patients with breast cancer, including 33 (28.0%) with biopsy-LPBC, 52 (44.1%) with TILs-US score-high, with 34 (28.8%) achieving pCR. The sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and AUC for predicting pCR were 0.53, 0.82, 2.96, 0.57, and 0.68, respectively, for biopsy-LPBC, and 0.76, 0.69, 2.47, 0.34, and 0.73, respectively, for TILs-US score. The biopsy-LPBC nomogram showed significant improvements in categorical NRI (p = 0.023) and IDI (p = 0.007) but not in AUC (p = 0.25), compared with the basic nomogram. The TILs-US nomogram exhibited significant improvements in AUC (p = 0.039), categorical NRI (p = 0.010), and IDI (p < 0.001).
CONCLUSIONS
CONCLUSIONS
The TILs-US score may serve as a novel marker for prediction of pCR in patients with breast cancer. An external validation study is warranted to confirm our findings.
Identifiants
pubmed: 39363123
doi: 10.1007/s10147-024-02634-9
pii: 10.1007/s10147-024-02634-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Klobuch S, Seijkens TTP, Schumacher TN et al (2024) Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nat Rev Clin Oncol 21(3):173–184. https://doi.org/10.1038/s41571-023-00848-w
doi: 10.1038/s41571-023-00848-w
pubmed: 38191921
Amaria R, Knisely A, Vining D et al (2024) Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. https://doi.org/10.1136/jitc-2023-006822
doi: 10.1136/jitc-2023-006822
pubmed: 38423748
pmcid: 11005706
Ding R, Prasanna P, Corredor G et al (2022) Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome. NPJ Precis Oncol 6(1):33. https://doi.org/10.1038/s41698-022-00277-5
doi: 10.1038/s41698-022-00277-5
pubmed: 35661148
pmcid: 9166700
Denkert C, von Minckwitz G, Darb-Esfahani S et al (2018) Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19(1):40–50. https://doi.org/10.1016/S1470-2045(17)30904-X
doi: 10.1016/S1470-2045(17)30904-X
pubmed: 29233559
Loi S, Drubay D, Adams S et al (2019) Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol 37(7):559–569. https://doi.org/10.1200/JCO.18.01010
doi: 10.1200/JCO.18.01010
pubmed: 30650045
pmcid: 7010425
Ingold Heppner B, Untch M, Denkert C et al (2016) Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer. Clin Cancer Res 22(23):5747–5754. https://doi.org/10.1158/1078-0432.CCR-15-2338
doi: 10.1158/1078-0432.CCR-15-2338
pubmed: 27189162
Denkert C, von Minckwitz G, Brase JC et al (2015) Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 33(9):983–991. https://doi.org/10.1200/JCO.2014.58.1967
doi: 10.1200/JCO.2014.58.1967
pubmed: 25534375
Salgado R, Denkert C, Demaria S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259–271. https://doi.org/10.1093/annonc/mdu450
doi: 10.1093/annonc/mdu450
pubmed: 25214542
Seely JM, Hill F, Peddle S et al (2017) An evaluation of patient experience during percutaneous breast biopsy. Eur Radiol 27(11):4804–4811. https://doi.org/10.1007/s00330-017-4872-2
doi: 10.1007/s00330-017-4872-2
pubmed: 28534164
Khoury T, Peng X, Yan L et al (2018) Tumor-infiltrating lymphocytes in breast cancer: evaluating interobserver variability, heterogeneity, and fidelity of scoring core biopsies. Am J Clin Pathol 150(5):441–450. https://doi.org/10.1093/ajcp/aqy069
doi: 10.1093/ajcp/aqy069
pubmed: 30052720
Huang J, Chen X, Fei X et al (2019) Changes of tumor infiltrating lymphocytes after core needle biopsy and the prognostic implications in early stage breast cancer: a retrospective study. Cancer Res Treat 51(4):1336–1346. https://doi.org/10.4143/crt.2018.504
doi: 10.4143/crt.2018.504
pubmed: 30744321
pmcid: 6790848
O’Loughlin M, Andreu X, Bianchi S et al (2018) Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study. Breast Cancer Res Treat 171(1):1–9. https://doi.org/10.1007/s10549-018-4825-8
doi: 10.1007/s10549-018-4825-8
pubmed: 29774470
Fukui K, Masumoto N, Shiroma N et al (2019) Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer. Breast Cancer 26(5):573–580. https://doi.org/10.1007/s12282-019-00958-3
doi: 10.1007/s12282-019-00958-3
pubmed: 30868399
Kanou A, Masumoto N, Fukui K et al (2022) The tumor-infiltrating lymphocyte ultrasonography score can provide a diagnostic prediction of lymphocyte-predominant breast cancer preoperatively. J Med Ultrason. 49(4):709–717. https://doi.org/10.1007/s10396-022-01240-4
doi: 10.1007/s10396-022-01240-4
Kimura Y, Masumoto N, Kanou A et al (2022) The TILs-US score on ultrasonography can predict the pathological response to neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive and triple-negative breast cancer. Surg Oncol 41:101725. https://doi.org/10.1016/j.suronc.2022.101725
doi: 10.1016/j.suronc.2022.101725
pubmed: 35189516
Giuliano AE, Connolly JL, Edge SB et al (2017) Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(4):290–303. https://doi.org/10.3322/caac.21393
doi: 10.3322/caac.21393
pubmed: 28294295
Allison KH, Hammond MEH, Dowsett M et al (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol 38(12):1346–1366. https://doi.org/10.1200/JCO.19.02309
doi: 10.1200/JCO.19.02309
pubmed: 31928404
Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36(20):2105–2122. https://doi.org/10.1200/JCO.2018.77.8738
doi: 10.1200/JCO.2018.77.8738
pubmed: 29846122
DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845
doi: 10.2307/2531595
pubmed: 3203132
Kramer AA, Zimmerman JE (2007) Assessing the calibration of mortality benchmarks in critical care: the Hosmer-Lemeshow test revisited. Crit Care Med 35(9):2052–2056. https://doi.org/10.1097/01.CCM.0000275267.64078.B0
doi: 10.1097/01.CCM.0000275267.64078.B0
pubmed: 17568333
Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr et al (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27(2):157–172. https://doi.org/10.1002/sim.2929 . (Discussion 207-112)
doi: 10.1002/sim.2929
pubmed: 17569110
Kundel HL, Polansky M (2003) Measurement of observer agreement. Radiology 228(2):303–308. https://doi.org/10.1148/radiol.2282011860
doi: 10.1148/radiol.2282011860
pubmed: 12819342
Gao ZH, Li CX, Liu M et al (2020) Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. BMC Cancer 20(1):1150. https://doi.org/10.1186/s12885-020-07654-y
doi: 10.1186/s12885-020-07654-y
pubmed: 33238978
pmcid: 7690150
Zhang F, Huang M, Zhou H et al (2019) A nomogram to predict the pathologic complete response of neoadjuvant chemotherapy in triple-negative breast cancer based on simple laboratory indicators. Ann Surg Oncol 26(12):3912–3919. https://doi.org/10.1245/s10434-019-07655-7
doi: 10.1245/s10434-019-07655-7
pubmed: 31359285
Jimenez JE, Abdelhafez A, Mittendorf EA et al (2022) A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol 149:110220. https://doi.org/10.1016/j.ejrad.2022.110220
doi: 10.1016/j.ejrad.2022.110220
pubmed: 35193025
Yu Y, Wang Z, Wang Q et al (2023) Radiomic model based on magnetic resonance imaging for predicting pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Front Oncol 13:1249339. https://doi.org/10.3389/fonc.2023.1249339
doi: 10.3389/fonc.2023.1249339
pubmed: 38357424
Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164–172. https://doi.org/10.1016/S0140-6736(13)62422-8
doi: 10.1016/S0140-6736(13)62422-8
pubmed: 24529560
Barron AU, Hoskin TL, Day CN et al (2018) Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg 153(12):1120–1126. https://doi.org/10.1001/jamasurg.2018.2696
doi: 10.1001/jamasurg.2018.2696
pubmed: 30193375
pmcid: 6583006
Tasoulis MK, Lee HB, Yang W et al (2020) Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer. JAMA Surg 155(12):e204103. https://doi.org/10.1001/jamasurg.2020.4103
doi: 10.1001/jamasurg.2020.4103
pubmed: 33026457
pmcid: 7542519
Gharzai LA, Szczygiel LA, Shumway DA et al (2021) A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006). Breast Cancer Res Treat 187(3):777–784. https://doi.org/10.1007/s10549-021-06172-0
doi: 10.1007/s10549-021-06172-0
pubmed: 33740205
pmcid: 8648089
Heil J, Kummel S, Schaefgen B et al (2015) Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. Br J Cancer 113(11):1565–1570. https://doi.org/10.1038/bjc.2015.381
doi: 10.1038/bjc.2015.381
pubmed: 26554654
pmcid: 4705891
Janssen LM, den Dekker BM, Gilhuijs KGA et al (2022) MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis. NPJ Breast Cancer 8(1):107. https://doi.org/10.1038/s41523-022-00475-1
doi: 10.1038/s41523-022-00475-1
pubmed: 36123365
pmcid: 9485124
van Hemert AKE, van Duijnhoven FH, van Loevezijn AA et al (2023) Biopsy-guided pathological response assessment in breast cancer is insufficient: additional pathology findings of the MICRA trial. Ann Surg Oncol 30(8):4682–4689. https://doi.org/10.1245/s10434-023-13476-6
doi: 10.1245/s10434-023-13476-6
pubmed: 37071235
pmcid: 10319687
Shigematsu H, Fujisawa T, Shien T et al (2020) Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy. Jpn J Clin Oncol 50(6):629–634. https://doi.org/10.1093/jjco/hyaa055
doi: 10.1093/jjco/hyaa055
pubmed: 32378709
Jung JJ, Cheun JH, Kim SY et al (2024) Omission of breast surgery in predicted pathologic complete response after neoadjuvant systemic therapy: a multicenter, single-arm non-inferiority trial. J Breast Cancer 27(1):61–71. https://doi.org/10.4048/jbc.2023.0265
doi: 10.4048/jbc.2023.0265
pubmed: 38433091
pmcid: 10912576